October 5, 2022
Astellas Pharma said on October 3 that it has signed a technology evaluation contract with Germany-based Pantherna Therapeutics for research to develop regenerative medicine programs through mRNA-based direct reprogramming, also known as transdifferentiation. The new deal extends the scope of...read more